Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy
Study conducted with investigators at Dana-Farber Cancer Institute showed ctDNA changes pre- and post-ICI therapy associated with resistance to treatment; Suggests liquid biopsy may be a useful tool for personalizing immunotherapy in patients with metastatic urothelial carcinoma
Excerpt from the Press Release:
PALO ALTO, Calif.–(BUSINESS WIRE)–Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy. The data will be presented as part of a virtual poster presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
Urothelial carcinoma is the most common type of bladder cancer and immune checkpoint inhibitors (ICIs) are used as both first and second-line therapy for patients with metastatic urothelial carcinoma (mUC). Most mUC patients do not respond, or develop resistance to, ICI and obtaining tissue biopsies before and throughout treatment is invasive and presents risks of complications.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?